Literature DB >> 17768131

APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival.

Lourdes Planelles, Sonia Castillo-Gutiérrez, Jan Paul Medema, Antonio Morales-Luque, Hélène Merle-Béral, Michael Hahne.   

Abstract

APRIL (a proliferation-inducing ligand) and BLyS (B lymphocyte stimulator) expression have been reported in chronic lymphocytic leukemia (CLL) cells. We examined APRIL and BLyS serum levels in CLL patients and evaluated the prognostic significance of APRIL expression on survival.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17768131     DOI： 10.3324/haematol.10317

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  16 in total

1.  Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies.

Authors:  Stephen A Mihalcik; Renee C Tschumper; Diane F Jelinek
Journal:  Cell Cycle       Date:  2010-12-15       Impact factor: 4.534

2.  Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma.

Authors:  Stephen M Ansell; Anne J Novak; Steven Ziesmer; Tammy Price-Troska; Betsy LaPlant; Stacey R Dillon; Thomas E Witzig
Journal:  Am J Hematol       Date:  2009-02       Impact factor: 10.047

3.  The TNF family member APRIL promotes colorectal tumorigenesis.

Authors:  V Lascano; L F Zabalegui; K Cameron; M Guadagnoli; M Jansen; M Burggraaf; M Versloot; H Rodermond; C van der Loos; C E Carvalho-Pinto; H Kalthoff; J P Medema; M Hahne
Journal:  Cell Death Differ       Date:  2012-06-15       Impact factor: 15.828

4.  Prognostic Significance of Serum BAFF, APRIL, TACI and BCMA Levels in Chronic Lymphocytic Leukemia.

Authors:  İlay Berke Menteşe; Zeynep Arzu Yegin; Sanem Gökçen; Zübeyde Nur Özkurt; Münci Yağcı
Journal:  Indian J Hematol Blood Transfus       Date:  2018-10-10       Impact factor: 0.900

5.  APRIL induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway.

Authors:  Guihua Wang; Feng Wang; Weifeng Ding; Jingchun Wang; Rongrong Jing; Haiquan Li; Xudong Wang; Yueguo Wang; Shaoqing Ju; Huimin Wang
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

6.  Study of the quantitative, functional, cytogenetic, and immunoregulatory properties of bone marrow mesenchymal stem cells in patients with B-cell chronic lymphocytic leukemia.

Authors:  Charalampos Pontikoglou; Maria-Christina Kastrinaki; Mirjam Klaus; Christina Kalpadakis; Pavlos Katonis; Kalliopi Alpantaki; Gerassimos A Pangalis; Helen A Papadaki
Journal:  Stem Cells Dev       Date:  2013-02-01       Impact factor: 3.272

7.  APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

Authors:  Yu-Tzu Tai; Chirag Acharya; Gang An; Michele Moschetta; Mike Y Zhong; Xiaoyan Feng; Michele Cea; Antonia Cagnetta; Kenneth Wen; Hans van Eenennaam; Andrea van Elsas; Lugui Qiu; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

8.  Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.

Authors:  Valeria Lascano; Marco Guadagnoli; Jan G Schot; Dieuwertje M Luijks; Jeroen E J Guikema; Katherine Cameron; Michael Hahne; Steven Pals; Erik Slinger; Thomas J Kipps; Marinus H J van Oers; Eric Eldering; Jan Paul Medema; Arnon P Kater
Journal:  Blood       Date:  2013-10-07       Impact factor: 22.113

9.  TACI expression and signaling in chronic lymphocytic leukemia.

Authors:  Antigoni Mamara; Anastasios E Germenis; Maria Kompoti; Maria Palassopoulou; Eudokia Mandala; Anastasia Banti; Nikolaos Giannakoulas; Matthaios Speletas
Journal:  J Immunol Res       Date:  2015-04-09       Impact factor: 4.818

10.  Synovial tissues concentrate secreted APRIL.

Authors:  Cem Gabay; Veit Krenn; Carine Bosshard; Christian Alexander Seemayer; Carlo Chizzolini; Bertrand Huard
Journal:  Arthritis Res Ther       Date:  2009-09-29       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.